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Abstract
Background: Migration and invasion enhancer 1 (MIEN1) is a novel gene found to be abundantly expressed in
breast tumor tissues and functions as a critical regulator of tumor cell migration and invasion to promote systemic
metastases. Previous studies have identified post-translational modifications by isoprenylation at the C-terminal tail
of MIEN1 to favor its translocation to the inner leaflet of plasma membrane and its function as a membrane-bound
adapter molecule. However, the exact molecular events at the membrane interface activating the MIEN1-driven tumor
cell motility are vaguely understood.
Methods: MIEN1 was first studied using in-silico analysis on available RNA sequencing data of human breast tissues and
its expression was ascertained in breast cells. We performed several assays including co-immunoprecipitation, wound
healing, western blotting and immunofluorescence to decipher the molecular events involved in MIEN1-mediated tumor
cell migration.
Results: Clinically, MIEN1 is predominantly overexpressed in Her-2 and luminal B subtypes of breast tumors, and its
increased expression correlates with poor disease free survival. Molecular studies identified a phosphorylation-
dependent activation signal in the immunoreceptor tyrosine based activation motif (ITAM) of MIEN1 and the
phosphorylation-deficient MIEN1-mutants (Y39F/50 F) to regulate filopodia generation, migration and invasion.
We found that ITAM-phosphorylation of MIEN1 is significantly impaired in isoprenylation-deficient MIEN1 mutants
indicating that prenylation of MIEN1 and membrane association is required for cross-phosphorylation of tyrosine residues.
Furthermore, we identified MIEN1 as a novel interactor of Annexin A2 (AnxA2), a Ca2+ -dependent phospholipid binding
protein, which serves as an extracellular proteolytic center regulating plasmin generation. Fluorescence resonance energy
transfer (FRET) confirmed that MIEN1 physically interacts with AnxA2 and functional studies revealed that they mutually
cooperate to accentuate tumor cell motility. Interestingly, our study identified that ectopic overexpression of MIEN1
significantly enhances Tyr23-phosphorylation on AnxA2, thereby stimulating cell surface translocation of AnxA2 and
catalyzing the activation of its proteolytic activity.
Conclusion: Our data show that the presence and interaction of both MIEN1 and AnxA2 in breast tumors are crucial
drivers of cell motility. Our study has now deciphered a novel regulatory network governing the vicious process of breast
tumor cell invasion-metastasis, and findings suggest MIEN1-AnxA2 as prospective targets to counter the deadly disease.
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Introduction
Migration and invasion enhancer 1(MIEN1) (also known
as C35, C17orf37, RDX12, and MGC14832) is located in
the chromosomal region 17q12-21, in the ERBB2 ampli-
con [1–4]. MIEN1 is frequently amplified along the neigh-
boring genes, ErBB2 and GRB7 in variety of tumors
including breast cancer. Our previous studies identified
MIEN1 as the prime regulator of cancer cell migration
and invasion [5]. In addition, we demonstrated that
MIEN1 has a functional isoprenylation ‘CAAX’ motif at
the C-terminal tail that is post-translationally modified
by geranyl-geranyl transferase-I (GGTase-I) [6]. Prenylated
MIEN1 then translocates to the inner leaflet of the plasma
membrane and potentiates filopodia formation whereas
prenylation-deficient MIEN1-mutants fail to migrate, in-
vade and display reduced metastatic capacity in cancer
mouse models. However, the exact molecular events at
the membrane interface in MIEN1-driven breast tumor
cell motility are poorly understood.
The onset of metastasis depends primarily on the abil-
ity of tumor cells to detach from basement membranes
by cleaving extracellular matrix proteins and promoting
motility and invasion to propel forward [7–11]. One of
the key factors regulating the extracellular proteolytic
process is the plasmin-plasminogen system; which is com-
posed of a proteolytic cascade comprising the two plas-
minogen activators- tissue plasminogen activator (tPA)
and urokinase plasminogen activator (uPA) [12–18]. Acti-
vation of this proteolytic cascade converts the inactive
trypsin-like endopeptidases into potent plasmin, which
then cleaves the components of the extracellular matrix
proteins thereby facilitating rapid migration and invasion
of tumor cells to distant organs.
Here, we report that MIEN1 regulates breast cancer cell
migration and invasion in a bifunctional mechanism. We
show that MIEN1 has a functional immunoreceptor tyro-
sine based activation motif (ITAM) cross-phosphorylated
at two tyrosine-residues (Y39 and Y50), which is im-
portant for triggering downstream signal transduction.
In addition, we discovered MIEN1 as a novel interacting
partner of Annexin A2, a member of the Annexin family
of Ca2+-dependent phospholipid binding proteins [19, 20].
Functional studies confirmed interaction of MIEN1 with
AnxA2 at the membrane interface is necessary for activa-
tion of plasmin-plasminogen complex, thereby facilitating
breast cancer cell migration and invasion. Our study iden-
tified a novel regulatory pathway for activating extracellu-
lar plasmin generation to promote enhanced breast cancer
cell migration and invasion.
Results
MIEN1 is expressed in all subtypes of breast cancer
Enhanced expression of MIEN1 is reported in breast
cancer compared to normal breast tissues [2]. Analysis
of Cancer Genome Atlas (TCGA) data sets identified sig-
nificantly elevated MIEN1 expression in different subtypes
of breast carcinomas (Apocrine, Large Cell Neuroendo-
crine, Cribiform, Papillary, Ductal, Lobular, Mixed Ductal
and Lobular, Mucinous) patients compared to normal tis-
sues (Fig. 1a). In clinical oncology, evaluations of breast
tumors are accompanied by an assessment of the molecu-
lar status of ER, PR and Her-2 oncogene. To understand
the differential expression of MIEN1 in various subtypes
of breast cancer, we examined the expression of MIEN1
within the molecular subtypes of breast cancer. Our find-
ings revealed that MIEN1 is predominantly overexpressed
in Her-2 positive (85 % cases with elevated MIEN1) and
luminal B (63 % cases with elevated MIEN1) subtypes.
However, MIEN1 expression in other subtypes basal-like
and luminal A were moderate, whereas majority of the
normal breast tissues had low MIEN1 (Fig. 1b). Screening
of various established breast tumor lines identified in-
creased expression of MIEN1 in majority of the breast
tumor lines (MCF10AT, MCF10CA1a, MCF10CA1d,
MCF10CA1h, JIMT-1, BT-474, SKBR-3, MDA-MB231,
T47D, MCF-7, MDA-MB436 and HCC-70) compared to
the immortalized normal mammary epithelial cell line,
MCF10A (Fig. 1c). As expected most of the Her-2 ampli-
fied cell lines displayed increased expression of MIEN1
protein (CRL-2330, SKBR-3, and BT-474); but MIEN1 ex-
pression is not only restricted to Her-2 amplification indi-
cating its distinct transcriptional and post-translational
modifications contributing to its elevated expression in
breast tumors. Classification of the patient cohort accord-
ing to high and low MIEN1 expression using TCGA data-
set, confirmed a poor survival in breast cancer patients
with elevated MIEN1 expression as previously shown [21]
(Fig. 1d). Altogether, these findings confirm that MIEN1 is
a clinically important oncogene, and its increased ex-
pression contributes towards an aggressive disease with
poor survival.
MIEN1 has a functional ITAM-motif
In addition to isoprenylation motif [6], MIEN1 harbors
several potential phosphorylation sites. Analysis of MIEN1
sequence using computational algorithms (KinasePhos 2.0)
identified four potential phosphorylated tyrosine resi-
dues (Tyr29, Tyr39, Tyr50 and Tyr85) [22–25] of which
Tyr39 and Tyr50 residues are located in the ITAM do-
main [21]. The canonical ITAM (immunoreceptor tyro-
sine based activation motif) is an 18 sequence amino acids
(YxxI(6–8)YxxL) where tyrosine is separated from a leucine
or isoleucine by any two other amino acids, giving the sig-
nature YxxL/I; and these two signatures are typically sepa-
rated by 6 to 8 amino acids. To demonstrate that the Y39/
Y50 in the ITAM domain of MIEN1 is phosphorylated, we
investigated the phosphorylation status of MIEN1 (Fig. 2a).
Immunoprecipitation of GFP-tagged MIEN1 constructs
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followed by immunoblot analysis using a generic phospho-
tyrosine antibody, demonstrated that MIEN1 wild type
(MIEN1WT) is tyrosine phosphorylated, whereas the Y39F
and Y50F phospho-deficient mutants showed lower phos-
phorylation status. However Y50F mutant showed a greater
loss of phosphorylation compared to Y39F (Fig. 2b). Re-
placement of Y39 and Y50 with phenylalanine (Y39/Y50F)
reduced MIEN1-tyrosine phosphorylation by half; indicat-
ing that there is some background phosphorylation on the
tyrosine residues outside the ITAM domain.
Since, MIEN1 is also modified by isoprenylation at the
C-terminal ‘CVIL’ end responsible for its membrane
localization [6], we investigated whether phosphorylation
of ITAM-tyrosine residues is dependent on isoprenylation.
For this, we analyzed the tyrosine-phosphorylation sta-
tus of MIEN1 in NIH3T3 cells (with low endogenous
MIEN1) transfected with GFP vector only, MIEN1WT or
prenylation-deficient MIEN1C112S constructs. In addition,
the MIEN1WT expressing cells were either treated with
a pharmacological inhibitor against GGTase enzyme
GGTI (geranylgeranyl transferase I inhibitor) or vehicle
control (DMSO). MIEN1WT expressing cells showed
robust tyrosine-phosphorylation whereas GGTI treatment
severely abrogated the effect similar to the MIEN1C112S
expressing cells (Fig. 2c). These data indicate that
tyrosine-phosphorylation of MIEN1 in the ITAM-domain
is dependent on prior isoprenylation. These results
demonstrate that correct localization of the protein to
Fig. 1 Expression of MIEN1 in breast cancer patient specimens and cultured cell lines. a Expression of MIEN1 in different subtypes of breast
cancer patients as obtained by analyzing TCGA dataset from Oncomine. Legends and number of tissues analyzed are in parentheses- 0. No value
(normal) (n = 61); 1. Apocrine Breast Carcinoma (n = 1); 2. Breast Large Cell Neuroendocrine Carcinoma (n = 1); 3. Ductal Breast Carcinoma (n = 1);
4. Intraductal Cribriform Breast Adenocarcinoma (n = 3); 5. Invasive Breast Carcinoma (n = 76); 6. Invasive Cribriform Breast Carcinoma (n = 1); 7.
Invasive Ductal Breast Carcinoma (n = 392); 8. Invasive Ductal and Lobular Carcinoma (n = 3); 9. Invasive Lobular Breast Carcinoma (n = 36); 10.
Invasive Papillary Breast Carcinoma (n = 1); 11. Male Breast Carcinoma (n = 3); 12. Metaplastic Breast Carcinoma (n = 1); 13. Mixed Lobular and
Ductal Breast Carcinoma (n = 7); 14. Mucinous Breast Carcinoma (n = 4); 15. Papillary Breast Carcinoma (n = 1); 16. Pleomorphic Breast Carcinoma
(n = 1). b MIEN1 mRNA expression in different molecular subtypes of breast cancer as determined by RSSPC using bc-GenExMiner database v3.0.
A. The figure and table show the patients with low, intermediate and high MIEN1 expression in each molecular subtype. c MIEN1 protein expression
was analyzed by immunoblotting analysis and β-actin was used as loading control. d Kaplan Meier survival curve showing the survival percentage of
breast cancer patients were significantly low in MIEN1-high expressing tumors compared to low-expressing cohort. TCGA data analyzed using UCSD
cancer genome browser
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the plasma membrane is required for subsequent post-
translational modification via tyrosine-phosphorylation
at the ITAM-domain.
Relative importance of ITAM and CAAX motifs in MIEN1-
induced migration
Next, we evaluated the functional impact of MIEN1-
ITAM and isoprenyl mutants compared to the wild-type
protein (MIEN1WT). For this, we stably expressed MIEN1
constructs in NIH3T3-cells with low endogenous protein.
Cell migration was significantly enhanced in cells express-
ing MIEN1WT relative to the vector control (Fig. 3a, b),
whereas MIEN1C112S failed to migrate into the wound
(Fig. 3c), as reported earlier [6]. Similar to the isoprenyl-
mutants, NIH3T3 expressing ITAM mutants had a reduced
migratory potential (Fig. 3d–f ). However, we did not
observe significant differences in functional contribu-
tion between individual tyrosine mutants (MIEN1Y39F
and MIEN1Y50F) compared to MIEN1Y39/50F confirming
that the phosphorylation of both tyrosine residues is
vital for ITAM induced functions or signaling events to
mediate cell migration. The MIEN1Y39/50F/C112S cells did
not show any additive effect suggesting both isoprenylation
and ITAM-phosphorylation are important for MIEN1 func-
tion (Fig. 3g). To determine whether MIEN1 posttransla-
tional modifications are also required for invasive function,
we performed matrigel invasive assays with MDA-MB231
cells transfected with MIEN1 constructs. Consistent with
the data from the migration assays, MIEN1WT expression
increased the invasive potential of breast cancer cells whereas
Fig. 2 MIEN1 has a functional immunoreceptor tyrosine based activation motif. a Schematic representation of the ITAM and CAAX-prenylation motif
on MIEN1 protein and different site directed mutants used in the current study. Tyrosine residues in ITAM domain were mutated to phenylalanine (F)
and cysteine residue of the CAAX-prenylation site was mutated to serine (S). b NIH3T3 cells were transfected with GFP fused MIEN1WT, MIEN1Y39F,
MIEN1Y50F and MIEN1Y39/50F constructs followed by immunoprecipitation using GFP antibody. The tyrosine phosphorylation of MIEN1 was detected
using a generic phospho-tyrosine antibody. c NIH3T3 cells were transfected with empty GFP, MIEN1WT and MIEN1C112S constructs. MIEN1WT transfected
cells were either treated with DMSO (vehicle control) or geranylgeranyl transferase I (GGTI) inhibitor and then immunoprecipitated using GFP antibody
followed by immunoblotting with phospho-tyrosine antibody. The total MIEN1 protein used for immunoprecipitation was indicated as input
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ITAM and isoprenyl mutants failed to show an invasive
phenotype (Additional file 1: Figure S1).
Cell migration is the result of coordination between
membrane protrusive structures at a leading edge, adhe-
sion and de-adhesion followed by translocation of the
cell body in the direction of migration. In migrating
cells, protrusive structures such as filopodia are the pio-
neers, which probe the environment for cues and guide
cell migration. MIEN1 has been shown to induce filo-
podia formation and mutation of the isoprenyl motif im-
paired this function [6]. Here we inquired whether the
ITAM regulates MIEN1-induced filopodia, aside from
the isoprenyl motif. NIH3T3 cells expressing various
constructs of MIEN1 were stained with rhodamine-
conjugated phalloidin and subjected to immunofluores-
cence analysis post wound induction. Stable expression
of MIEN1 in NIH3T3 cells visibly increased the number
and length of filopodia post wound induction compared
to MIEN1-mutants expressing cells (Fig. 3i–n) confirm-
ing that ITAM and CAAX are important for MIEN1
function. Immunoblotting analysis of cells expressing
vector control and MIEN1 constructs confirmed the
equal expression of the wild type and mutants MIEN1
protein (Fig. 3o).
Fig. 3 Posttranslational modifications on MIEN1 regulate its function. NIH3T3 cells transfected with the MIEN1 constructs indicated in Fig. 2a,
were subjected to scratch wound assays. a–g Confluent monolayers of cells were wounded, and healing of the wound by cell migration was
monitored for 18 h. Images were taken at 0 and 18 h. h The fold change in migration was normalized to GFP (empty vector) transfected cells
and expressed as the means ± s.e.m of three independent experiments. i–n NIH3T3 cells transfected with indicated GFP-tagged MIEN1 constructs
were stained with rhodamine-conjugated phalloidin post wound induction to evaluate effects of ITAM and CAAX motif on filopodia formation.
o NIH3T3 cells expressing the GFP vector control and GFP-MIEN1 variants were analyzed for GFP and MIEN1 contents. GAPDH served as a loading control
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MIEN1 is an interactor of AnxA2
We investigated the potential interacting partners of
MIEN1 to define the mechanisms associated with tumor
cell migration and invasion. In a yeast two-hybrid assay,
we identified MIEN1 as potential interactor of AnxA2, a
Ca(2+)-dependent phospholipid binding protein which
translocates to the cell surface upon cellular signaling.
Full-length AnxA2 cDNA cloned into GAL4 DNA-binding
domain (GAL4 DNA-BD) of vector pGBKT7 was found to
interact with MIEN1 in a yeast two-hybrid screen from a
transformed human placental cDNA library as bait. Positive
clones were selected on high-stringency medium (synthetic
dropout medium) selection markers SD/−Ade/−His/−Leu/
−Trp/X-α-gal, and only true interactor-MIEN1 could acti-
vate the expression of β-galactosidase (blue color). The left
panel shows positive interaction of MIEN1 with AnxA2,
but not with p53. The right panel shows the positive
control p53 − T-antigen interaction, while the AnxA2 −
p53 interaction served as the negative control (Fig. 4a).
Following immunoblotting and real-time PCR analysis
of breast cell lines expressing both MIEN1 and AnxA2
(Additional file 2: Figure S2A-B), we performed co-
immunoprecipitation of endogenous AnxA2 with MIEN1
in BT-474 cells to confirm the yeast two-hybrid data. The
reciprocal immunoprecipitation of MIEN1 also pulled
down endogenous AnxA2, confirming that these two pro-
teins indeed reside in a complex. The total input used for
the immunoprecipitation confirmed equal loading and
similar levels of expression of both the proteins (Fig. 4b).
Colocalization experiments using confocal microscopy
also confirmed interaction of endogenous AnxA2 and
MIEN1 primarily in the cytosol, plasma membrane and
the perinuclear area of breast cancer cells (Fig. 4c). Finally
to confirm that AnxA2 and MIEN1 physically interact
intracellularly, we performed FRET detection by fluor-
escence lifetime imaging microscopy (FLIM) assay to
measure the proximity of MIEN1 and AnxA2. The life-
time decays of the donor (MIEN1) and donor-acceptor
(MIEN1-AnxA2) pair were measured to be 1.75 and
1.26 ns, respectively. Substituting the lifetime values in
the Förster equation, the efficiency of energy transfer
was determined to be 28 %, which corresponds to a dis-
tance of 50.3 Å between the donor and acceptor pair;
indicating that MIEN1 and AnxA2 indeed physically
interact and reside in a very close proximity (Fig. 4d).
These studies clearly validate MIEN1 as a novel inter-
actor of AnxA2.
MIEN1 enhances AnxA2 phosphorylation to promote cell
surface translocation and breast cancer cell migration
We investigated the effects of MIEN1 and AnxA2 inter-
action on cell migration, given their independent impli-
cations in cell migration and invasion (Fig. 5a-c). We
silenced MIEN1 and AnxA2 alone or in combination
(Fig. 5b) and examined the effects on motility of MDA-
MB231 cells. In monolayer migration assays, the wound
closure of cells with MIEN1 knockdown was significantly
inhibited compared to siGFP (control) transfected MDA-
MB231 cells (Fig. 5a, Additional file 3: Figure S3A-B). Silen-
cing of AnxA2 resulted in impairment of cell motility at 6
and 12 h following wound creation (Fig. 5a, Additional file
3: Figure S3A-B). Using similar knockdown strategy, we ob-
served that dual depletion of MIEN1 and AnxA2 led to a
two-fold decrease compared to siGFP (Fig. 5c), indicating
that MIEN1 and AnxA2 functionally cooperate to promote
breast cancer cell migration. AnxA2 is a phospholipid bind-
ing protein localizing to the plasma membrane towards the
cytosolic side. Previous studies proved that the phosphoryl-
ation of AnxA2 at the Y23 residue in the N-terminus of the
protein causes its translocation to the extracellular surface,
thereby activating extracellular proteolysis [26, 27]. To ver-
ify whether MIEN1 expression affects AnxA2 phosphoryl-
ation and subsequent translocation to the extracellular
surface, we performed immunoblotting analysis followed by
total internal reflection microscopy (TIRF-M). As shown in
Fig. 5d, over-expression of MIEN1 enhanced AnxA2 phos-
phorylation at Y23. Conversely, down-regulation of MIEN1
led to a decreased phosphorylation of AnxA2 at Y23
(Fig. 5e). To further confirm this observation, we performed
total internal reflection fluorescence microscopy (TIRF-M)
in MDA-MB231 cells. Stable MDA-MB231 cells expressing
vector control or MIEN1WT were probed with AnxA2 and
phospho-AnxA2Tyr23 antibodies followed by TIRF mi-
croscopy to determine cell surface total-AnxA2 and
phospho-AnxA2. MIEN1 overexpression significantly
enhanced phosphorylation of AnxA2 at the tyrosine 23
residue and subsequently cell surface localized AnxA2
levels; indicating MIEN1 dependent signaling and inter-
action activate AnxA2 function (Fig. 5f ).
MIEN1 activates AnxA2 dependent extracellular
proteolytic functions
Extracellular surface localized AnxA2 functions as a re-
ceptor for tPA and plasminogen; by binding to both en-
zymes, and catalytically activating plasmin generation
[28, 29]. Increased levels of plasmin enhance proteolytic
cleavage of ECM thus allowing cancer cells to migrate and
invade to distant sites. To confirm that MIEN1 regulates
AnxA2 dependent plasmin generation, we investigated the
effects of MIEN1 ablation either alone or in combination
with AnxA2 plasmin generation in breast cancer cells.
Using basal-like HCC70 and luminal MCF7 cells (these two
lines express high levels of both AnxA2 and MIEN1), we
inquired whether the interaction of MIEN1 and AnxA2
had an effect on plasmin generation. We first confirmed
siRNA-mediated knockdown of MIEN1 and AnxA2 in
HCC-70 and MCF-7 (Fig. 6a, c) respectively. Western blot-
ting analysis confirmed that the expression of MIEN1 or
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AnxA2 was dramatically reduced in the cells upon transfec-
tion with either MIEN1 or AnxA2 siRNA. Next, we exam-
ined the biochemical conversion of plasminogen to plasmin
in both cell lines upon siRNA treatment. Silencing of both
MIEN1 and AnxA2 led to a significant decrease in plasmin
levels in both HCC-70 and MCF-7 (P < 0.05) (Fig. 6b, d).
While the knockdown of AnxA2 led to a decrease in plas-
minogen conversion to plasmin in the initial hours as previ-
ously shown [30], the total change in plasmin levels were
insignificant compared to the control siRNA treated cells.
Interestingly, suppression of MIEN1 in MCF-7 cells led
to approximately 1.7 fold decrease in plasmin levels but
not in HCC-70; a difference which can be attributed to
the expression of various regulators of the plasminogen-
plasmin system. Taken together, these data indicate that
co-expression of both AnxA2 and MIEN1 enhance plasmin
generation and lead to an increase in breast tumor cell mi-
gration and invasion which in turn drive the metastatic
process.
Discussion
Cell motility process is a highly coordinated event inte-
grated by extensive transient signaling networks of proteins
[31, 32]. Protein–protein interactions are the underlying
backbone of migratory processes including actin structures,
proteolytic enzymes that degrade the ECM and the coord-
ination between detachment/re-adhesion cycles [33]. Here
we report the dynamics of MIEN1-induced signaling that
regulate tumor cell migration and invasion.
MIEN1 expression is significantly increased in breast can-
cer cells and analysis of TCGA database showed that ele-
vated expression of MIEN1 correlates with poor survival of
Fig. 4 MIEN1 is a novel interactor of AnxA2. a MIEN1 interacts with AnxA2 in a yeast two-hybrid screen. Positive clones were selected on high-stringency
medium (synthetic dropout medium) selection markers SD/−Ade/−His/−Leu/−Trp/X-α-gal, and only true interactors can activate the
expression of β-galactosidase (blue color). The left panel shows positive interaction of MIEN1 with AnxA2, but not with p53. The right panel
shows the positive control p53− T-antigen interaction, while the AnxA2 − p53 interaction served as the negative control. b Co-immunoprecipitation of
AnxA2 and MIEN1 in BT-474 cells showing the interaction of the two proteins. IgG was used as isotype control antibody and the total MIEN1 and
AnxA2 used for the experiment was shown by western blotting. c Confocal microscopy showing co-localization of AnxA2 and MIEN1 in cancer cells.
The interaction is predominantly observed around the membrane and cytosol excluding the nucleus. HCC-70, MCF-7 images were acquired with 40x
objective with 1x zoom; MDA-MB231 images were acquired with 40x objective with 2x zoom. d FRET confirms the interaction of MIEN1 and AnxA2.
Lifetime decays of the donor and donor − acceptor pair was measured to be 1.75 and 1.26 ns, respectively, and the lifetime decay histograms of the
donor − acceptor pair (upper) and donor (lower) are shown
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breast cancer patients. Several post-translational modifica-
tions regulate MIEN1 protein functions and downstream
signaling events. In addition to isoprenylation, in this study
we identified that phosphorylation of tyrosine residues
(Y39 and Y50) in the ITAM motif is important for its
function. Signal transduction by ITAM is initiated by the
Fig. 5 MIEN1 activates translocation of AnxA2 to plasma membrane to promote breast cancer cell migration. a Control and MIEN1 transfected
MDA-MB231 cells were subjected to western blot analysis with anti-MIEN1 or anti-AnxA2 antibody. PGK served as a loading control. b Down-regulation of
MIEN1 and AnxA2 reduces the abilities of MDA-MB231 breast cancer cells to migrate in vitro. Confluent MDA-MB231 monolayers transfected with control
GFP, AnxA2 or/and MIEN1 were wounded using a pipet tip, 60 h after transfection. Following the wound formation, plates were incubated for 12 h and
the wound closure areas were visualized on an Olympus Microscope (Carl Zeiss). Representative images were acquired at 0 and 12 h. c Quantification of
cell migration was achieved using Image J software. Data are presented as percentages of the recovered scratch area relative to untreated control cells.
Columns are the means five replicates from two independent experiments and bars are s.d. d MDA-MB231 and MDA-MB231 cells stably transfected
with control GFP or GFP-MIEN1WT were subjected to western blot analysis with anti-phosho AnxA2, anti-AnxA2 and anti-MIEN1 antibodies. GAPDH
served as a loading control. The quantification of the representative blots is the densitometric average of three independent experiments analyzed
using ImageJ and normalized to GAPDH. e Control and MIEN1 transfected MDA-MB231 cells were subjected to western blot analysis with anti-phosho
AnxA2, AnxA2, anti-MIEN1 and actin as loading control. f Representative images, as captured using a 60X oil immersion TIRF microscope, of MDA-MB231
and MDA-MB231 cells stably transfected with GFP-MIEN1WT grown to sub-confluence on coverslips, fixed with PFA, unpermeabilized, and processed for
TIRF microscopy with the specific antibodies. At least three independent fields were analyzed for confirmation of the staining pattern represented. Scale
bar denotes 20 μm
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phosphorylation of the tyrosine residues within the ITAM
sequence, followed by the recruitment of members of the
Syk kinase family [34–36]. The binding of Syk to the
phosphorylated-ITAM results in the activation of multiple
signaling cascades. Previous studies indicated that Syk
kinase potentiates MIEN1 dependent signaling in breast
tumor cells [21]. Using phospho-deficient single or double
mutants, we show that MIEN1 is tyrosine phosphorylated
in the ITAM motif. In addition, we also demonstrate that
isoprenylation and membrane localization is important for
ITAM-phosphorylation. Blocking isoprenylation of MIEN1
using GGTase inhibitors or genetic mutation of the
‘CVIL’ prenylation domain significantly impairs ITAM-
or tyrosine phosphorylation. These findings indicate
that ITAM-dependent signal transduction by MIEN1 de-
pends on prior isoprenylation and correct localization of
the protein to the inner leaflet of plasma membrane. As
expected, ITAM phosphorylation was also important for
MIEN1-dependent migration and invasion as phospho-
deficient MIEN1 mutants severely impaired breast cancer
cell migration and invasion.
Interestingly, we identified MIEN1 as an important
interactor of AnxA2. A multifunctional protein, AnxA2 is
involved in various cellular activities and its dysregulation
is implicated in multiple diseases including breast cancer
[37]. Although, AnxA2 is predominantly a cytosolic pro-
tein, phosphorylation on its N-terminal Y23 translocates
the protein to the cell surface [38, 39]. Cell surface AnxA2
Fig. 6 AnxA2 and MIEN1 silencing inhibit tPA dependent plasmin generation. Plasmin activity was determined at 460 nm using recombinant
plasminogen, TPA and fluorogenic plasmin substrate D-VLK-AMC. Western blotting was performed to confirm depletion of MIEN1 and AnxA2 in
HCC-70 (a) and MCF-7 (c) cells following siRNA knockdown. PGK served as a loading control. Total fold change in plasmin level in HCC-70 (b) and
MCF-7 (d) cells was calculated by normalizing the initial rates of plasmin in untreated cells (which were assigned a value of 1). The data is presented as
means ± s.d. (n = 6 for untreated controls and n = 6 for siRNA treatments)
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interacts with plasminogen and tPA and mediates the con-
version of plasminogen to plasmin [40]. In breast cancer,
AnxA2 mediated plasmin activation is shown to be essen-
tial for angiogenesis, migration and invasion which are
critical events in disease metastasis.
Our data provide evidence that MIEN1 interaction with
AnxA2 enhances Y23 phosphorylation of AnxA2 and sub-
sequent translocation of the protein to the cell surface
leads to increased plasmin levels which support breast
tumor cell motility. Although, MIEN1 does not have a
kinase domain, we believe this phosphorylation on AnxA2
is a downstream signaling event regulated by MIEN1.
Conclusion
Our studies convincingly demonstrate that interaction of
MIEN1 with AnxA2 is required for extracellular plasmin
generation thereby increasing breast cancer cell migra-
tion and invasion. Our findings place MIEN1 and anxA2




MIEN1 was first studied using in-silico analysis on available
DNA microarray and RNA sequencing data of breast
tumors and normal tissues from TCGA website (http://can-
cergenome.nih.gov/) and the bc-GenExMiner database v3.1
(http://bcgenex.centregauducheau.fr/BC-GEM/GEM_Accuei
l.php?js=1). The breast cancer gene-expression Miner v3.1
was utilized to assess MIEN1 expression in breast cancer
molecular subtypes. Bc-GenEXMiner analyzes available gene
expression data sets from repositories such as Gene Expres-
sion Omnibus (GEO), Array Express and Stanford micro-
array database [41–43]. The analysis was performed through
a built-in robust single sample predictor (SSP) classification
(RSSPC), which includes intersection of three SSPs [44]. The
UCSC Cancer Genomics Browser can be accessed through
https://genome-cancer.ucsc.edu/ and following the central
hyperlink. The UCSC Cancer Genomics Browser displays
the genomic, clinical and annotation data in multiple views
[45–50]. We used the breast cancer gene expression (BRCA)
(IlluminaHiSeq) dataset followed by subgrouping for
C17orf37 (MIEN1) expression. Subgroups allow users to
group samples according to an arbitrary combination of an-
notation data values. We stratified the BRCA dataset accord-
ing to MIEN1 expression: low (green from 0.0 to −6.67) and
high (red from 1.0 to 6.34) followed by Kaplan Meier plot to
generate the survival percentage over time (days) with re-
spect to MIEN1 expression.
Plasmids
GFP-MIEN1 (MIEN1WT) was generated by PCR amplifi-
cation of full-length human MIEN1 cDNA (347 base
pairs) and directionally cloned into pEGFP-C1 vector as
previously described [5, 6]. GFP-MIEN1 mutants were
generated using QuikChange multi-site-directed muta-
genesis kit from Stratagene (La Jolla, CA, USA) from the
GFP-MIEN1WT template.
MIEN1 and AnxA2 small interfering RNA transfection in
breast cancer cells
Human MIEN1 smart pool siRNA and AnxA2 smart
pool siRNA were used for knock-down experiments
(Dharmacon, Lafayette, CO). Green fluorescent protein
(GFP) siRNA (Qiagen, Germatown, MD) served as control.
Breast cancer cells were transfected with siRNA duplex at a
concentration of 40 nM using Lipofectamine RNAiMAX
purchased from Invitrogen (Grand Island, NY, USA).
Cell lines and culture conditions
NIH3T3 mouse fibroblast cells and human breast cancer
cell lines (SKBR-3, BT-474, MDA-MB231, MDA-MB4-36,
HCC-70, HCC-1937, MCF-7, T47D) were obtained from
American type culture collection. MCF10A, MCF10AT,
MCF10CA1a, MCF10CA1d, MCF10CA1h cells were ob-
tained from Karmanos cancer center, and JIMT-1 from
Leibniz-Institut DSMZ. All cell lines were maintained in a
humidified incubator containing 5 % CO2/95 % air at 37 °C.
Stable NIH3T3 and MDA-MB231 cells expressing GFP-
MIEN1 constructs were generated using 500 μg/ml and
650 μg/ml G418 antibiotic (Invitrogen).
Yeast two-hybrid screening
A yeast two-hybrid screening was carried out as de-
scribed previously. Full-length human AnxA2 cDNA
(GenBank entry NM_004039) fragment was cloned into
pGBKT7 vector (Clontech). The recombinant plasmid
used was GAL4 DNA binding bait (DNA-BD/bait) and
transformed into AH109 yeast cells screened for growth
on synthetic dropout (SD/-Trp) medium. A human pla-
cental pre-transformed cDNA library (Clontech) was
used for screening interacting proteins. This library was
made using the recombinant vector pGADT7, which
contains the activation domain (DNA-Ac/library) with a
different nutrient marker -Leu and was transformed into
strain Y187 and screened for growth on SD/-Leu medium.
The interaction screening was conducted by mating the
DNA-BD/ bait strain and DNA-Ac/library strain, and the
positive clones were selected. Positive clones were se-
lected on high-stringency medium with selection markers
SD/-Ade/-His/-Leu/-Trp/ X-R-gal and then screened as
described above (Clontech). Positive yeast clones were se-
lected by prototrophy for histidine or expression of β-
galactosidase and then subjected to sequence analysis to
search for novel interacting proteins.
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FLIM based forster resonance energy transfer (FRET) assay
FRET was performed as described previously with minor
modifications [51]. Briefly, cells were immunostained for
MIEN1 and AnxA2, labeled with donor Alexa-488 and
acceptor fluorophore Alexa-594, respectively. Upon
transfer of energy from the donor to the acceptor, the
donor fluorophore’s lifetime was monitored as an indica-
tor for the presence or absence of FRET.
Determination of the förster distance (R0)
The transfer efficiency was assessed from the donor (D)
and the donor in the presence of the acceptor (D + A)
lifetimes using the equation below





Using the transfer efficiency, E (0.28) and the transfer
distance, R0 (43 Aο), the distance between the two mole-
cules was determined to be 50.3Aο
E ¼ R0ð Þ
6
R0ð Þ6 þ rð Þ6
¼ 0:28 ¼ 43ð Þ
6
43ð Þ6 þ rð Þ6 ¼ 50:3A
∘
Immnunoprecipitation and immunoblotting assays
Immunoprecipitation and immunoblotting were per-
formed as described previously [51]. In brief cells were
lysed with NP-40 lysis buffer supplemented with protease
and phosphatase inhibitor cocktail (Millipore, Billerica,
MA). The supernatants were taken as the total cell lysates;
and using protein A/G PLUS-Agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA), AnxA2 and MIEN1 were
immunoprecipitated. The immunoprecipitated proteins
were separated by SDS-PAGE and transferred to nitrocel-
lulose membranes for immunoblotting. The antibodies
used were MIEN1 from Abnova (Taipei, Taiwan), AnxA2
(Santa Cruz Biotechnology) and β-actin (Santa Cruz
Biotechnology)
Migration and invasion assay
Cells were grown in a monolayer and upon reaching
confluence, the cell layer was scratched using a sterile
micropipette tip. The wound was imaged at the indi-
cated time points following wound creation. Representa-
tive images were captured and analyzed using Image J
software. Invasion assays were performed using HTS
FluoroBlok multi well insert system from BD Falcon,
(San Jose, CA, USA) as previously described [6].
Immunofluorescence
Cells were fixed using 4 % paraformaldehyde (Affymetrix,
Santa Clara, CA, USA) and stained with rhodamine-
conjugated phalloidin, MIEN1 and AnxA2 primary anti-
bodies followed by Alexa Fluor 488 and 594 secondary
antibodies (Invitrogen). Cells were mounted on glass cov-
erslips with Prolong Gold mounting medium (Invitrogen).
Confocal images were acquired using Zeiss confocal micro-
scope LSM510.
Total internal reflection fluorescence (TIRF) microscopy
For TIRF microscopy, MDA-MB231 cells were grown on
coverslips and then transfected with empty vector or
GFP-MIEN1 wild type. The cells were fixed with 4 % para-
formaldehyde, permeabilized with 0.1 % Triton X-100,
washed with PBS and blocked with BSA. Cells were subse-
quently treated with AnxA2 (BD Biosciences) and
phospho-AnxA2 Tyr23 (Santa Cruz Biotechnology) anti-
bodies followed by AlexaFlour 488 conjugated secondary
antibody and mounted with Permafluor mounting
medium. For TIRF images, the cells were visualized on an
Olympus IX71 microscope with commercial TIRF attach-
ment as described previously by 60 × oil immersion
objective [5].
Plasminogen activation assays
The assay was performed according to the previously estab-
lished protocols [26]. In brief, HCC-70 and MCF-7 cells
were transfected with GFP, MIEN1 and/or AnxA2 siRNA.
Cells were then incubated with recombinant 10 nM human
tPA and 100 nM Glu-plasminogen and subsequently
treated with the fluorogenic plasmin substrate, D-VLK-
AMC (D-Val-Leu-Lys-7-amido-4-methylcoumarin; Sigma).
Substrate hydrolysis was measured for 12 h. Results were
obtained as fluorescence units (FUs) using a fluorescence
spectrophotometer (380 nm excitation and 460 nm emis-
sion wavelengths).
Statistical analyses
Data acquired from migration, invasion, immunofluores-
cence and plasmin generation assays were analyzed
using student t-test. The statistical analysis was per-
formed using Windows version of SPSS along with
GraphPad Prism 4.02 software. The ImageJ software was
used for wound healing assay analysis. Significance was
defined as *P < 0.05, **P < 0.01, ***P < 0.001 compared to
controls and between different treatment groups.
Additional files
Additional file 1: Figure S1. Posttranslational modifications on MIEN1
regulate its invasion function. (A-G) MDA-MB231 transfected cells were
prelabeled with calcein AM fluorescent dye and an invasion assay was
performed with 10 % serum as a chemoattractant in the lower chamber.
The fold change of invasion was normalized to GFP (empty vector) transfected
cells and expressed as the means ± S.E. of three independent experiments (O).
(TIFF 11758 kb)
Additional file 2: Figure S2. Expression of MIEN1 and AnxA2 in a panel
of breast cell lines. (A) The protein expressions of MIEN1 and AnxA2 were
analyzed by immunoblotting analysis. (B) Quantitative real time PCR
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showed the mRNA expressions of MIEN1 and AnxA2 in breast cell lines.
(JPEG 342 kb)
Additional file 3: Figure S3. MIEN1 and AnxA2 are required for
MDA-MB231 cell migration. MDA-MB231 cells were treated with AnxA2 or/
and MIEN1 siRNA/GFP siRNA for 72 h. Scratch was made using a pipet tip in
MDA-MB231 cells confluent monolayer and healing of the wound was
monitored. (A) Representative images were acquired at 0 and 6 h. (B) Graph
shows the percent wound closure at 6 h intervals after wound formation.
(JPEG 913 kb)
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